Revvity Board Declares Quarterly Dividend
Get Alerts RVTY Hot Sheet
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 0.3%
EPS Growth %: +2.5%
Join SI Premium – FREE
WALTHAM, Mass.--(BUSINESS WIRE)-- The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on May 10, 2024 to all shareholders of record at the close of business on April 19, 2024.
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more.
With 2022 revenue of more than $3 billion and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.
Stay updated by following our Newsroom, LinkedIn, X, YouTube, Facebook and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240125311370/en/
Media Relations:
Chet Murray
(781) 462-5126
[email protected]
Investor Relations:
Steve Willoughby
[email protected]
Source: Revvity
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Asana Achieves FedRAMP® Moderate Authorization for Asana Gov
- North and Latin American Partners Honored at Engage 2026 for Driving AI Business Outcomes
- Worksite Heat Stress Expert Encourages Employers to Use OSHA's New Guidance as a Blueprint for Compliance
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
DividendSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share